Genome & Company's latest marketcap:
As of 06/24/2025, Genome & Company's market capitalization has reached $61.58 M. According to our data, Genome & Company is the 27958th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.
| Market Cap | 61.58 M |
| Revenue (ttm) | 21.81 M |
| Net Income (ttm) | -13,921,831.91 |
| Shares Out | 31.09 M |
| EPS (ttm) | -0.45 |
| Forward PE | 0.00 |
| Ex-Dividend Date | n/a |
| Earnings Date | 08/14/2025 |
Genome & Company's yearly market capitalization.
| Date | Market Cap | Change (%) | Global Rank |
|---|---|---|---|
| 06/24/2025 | ₩61.58 M | -1.86% | 27958 |
| 12/30/2024 | ₩85.21 B | -51.64% | 27080 |
| 12/28/2023 | ₩176.21 B | -28.34% | 21156 |
| 12/29/2022 | ₩245.9 B | -47.55% | 18193 |
| 12/30/2021 | ₩468.83 B | -55.28% | 14822 |
| 12/30/2020 | ₩1.05 T | 224.28% | 8134 |
| 12/30/2019 | ₩323.32 B | 241.2% | 13139 |
| 12/28/2018 | ₩94.76 B | 18126 |
Company Profile
About Genome & Company
Genome & Company is a clinical-stage biotechnology firm based in Seongnam-si, South Korea. Founded in 2015, the company specializes in pioneering novel-targeted immuno-oncology therapeutics, with applications in skin diseases and autism spectrum disorders.
Key Product Candidates
- GEN-001: An oral microbiome therapeutic designed to modulate immune responses.
- GEN-501: Targets non-responders to Dupilumab drugs in patients with atopic skin diseases.
- GEN-104: Focused on treating solid tumors.
Additional Developments
The company also works on microbiome-based products, including:
- Therapeutics
- Cosmeceuticals
- Dietary supplements
Strategic Partnerships
Genome & Company collaborates with US-based Scioto Biosciences to develop SB-121, targeting:
- Gut-brain axis disorders (e.g., Autism Spectrum Disorder)
- Gut-injury conditions (e.g., Necrotizing Enterocolitis)
Frequently Asked Questions
-
What is Genome & Company's (KOSDAQ-314130) current market cap?As of 06/24/2025, Genome & Company (including the parent company, if applicable) has an estimated market capitalization of $61.58 M USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
-
Where does Genome & Company (KOSDAQ-314130) rank globally by market cap?Genome & Company global market capitalization ranking is approximately 27958 as of 06/24/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.